CN100546976C - 基于硝基苯胺的烷化剂和它们作为前体药物的用途 - Google Patents

基于硝基苯胺的烷化剂和它们作为前体药物的用途 Download PDF

Info

Publication number
CN100546976C
CN100546976C CNB2003801028127A CN200380102812A CN100546976C CN 100546976 C CN100546976 C CN 100546976C CN B2003801028127 A CNB2003801028127 A CN B2003801028127A CN 200380102812 A CN200380102812 A CN 200380102812A CN 100546976 C CN100546976 C CN 100546976C
Authority
CN
China
Prior art keywords
amino
etoac
compound
oso
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801028127A
Other languages
English (en)
Chinese (zh)
Other versions
CN1711236A (zh
Inventor
W·A·丹尼
G·J·阿特韦尔
杨尚金
W·R·威尔森
A·V·帕特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CN1711236A publication Critical patent/CN1711236A/zh
Application granted granted Critical
Publication of CN100546976C publication Critical patent/CN100546976C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB2003801028127A 2002-10-08 2003-10-08 基于硝基苯胺的烷化剂和它们作为前体药物的用途 Expired - Fee Related CN100546976C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ521851A NZ521851A (en) 2002-10-08 2002-10-08 Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
NZ521851 2002-10-08

Publications (2)

Publication Number Publication Date
CN1711236A CN1711236A (zh) 2005-12-21
CN100546976C true CN100546976C (zh) 2009-10-07

Family

ID=32089872

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801028127A Expired - Fee Related CN100546976C (zh) 2002-10-08 2003-10-08 基于硝基苯胺的烷化剂和它们作为前体药物的用途

Country Status (8)

Country Link
US (1) US7776924B2 (https=)
EP (1) EP1558568A4 (https=)
JP (2) JP4582519B2 (https=)
CN (1) CN100546976C (https=)
AU (1) AU2003278628B2 (https=)
CA (1) CA2501388C (https=)
NZ (1) NZ521851A (https=)
WO (1) WO2004033415A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004285831B2 (en) * 2003-10-31 2011-09-15 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
JP4761899B2 (ja) * 2005-09-12 2011-08-31 Ｈｏｙａ株式会社 電子内視鏡システム
NZ549659A (en) * 2006-09-04 2008-12-24 Auckland Uniservices Ltd Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom
EP2350664B1 (en) 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
CN101723932B (zh) * 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
ES2877629T3 (es) 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
EP2888227B1 (en) * 2012-08-23 2020-07-29 Convert Pharmaceuticals SA Novel prodrugs and methods of use thereof
US10202408B2 (en) 2012-08-23 2019-02-12 Health Innovation Ventures B.V. Prodrugs and methods of use thereof
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP2016528217A (ja) 2013-07-26 2016-09-15 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
JP7327900B2 (ja) 2015-06-24 2023-08-16 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド アジリジン含有ｄｎａアルキル化剤
CN106995815B (zh) * 2016-01-22 2020-09-01 南京农业大学 硝基还原酶基因pnr及其编码的蛋白和应用
CN106905184B (zh) * 2017-03-05 2019-03-29 北京化工大学 含有苯甲酰胺基团的氮芥类化合物及其制备方法和用途
EP3774743B1 (en) * 2018-03-29 2023-11-22 Achilles Medical Limited Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ240785A (en) * 1991-11-28 1995-08-28 Cancer Res Campaign Tech Substituted nitro aniline derivatives and medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mustard prodrugs for activation by escherichia colinitroreductase in gene-directed enzyme prodrug therapy. Frank Friedlos et al.J.Med.Chem.,No.40. 1997 *

Also Published As

Publication number Publication date
CN1711236A (zh) 2005-12-21
WO2004033415A1 (en) 2004-04-22
NZ521851A (en) 2005-02-25
CA2501388C (en) 2011-01-04
US20050256191A1 (en) 2005-11-17
JP2010265272A (ja) 2010-11-25
AU2003278628A1 (en) 2004-05-04
EP1558568A1 (en) 2005-08-03
JP4582519B2 (ja) 2010-11-17
CA2501388A1 (en) 2004-04-22
JP2006502214A (ja) 2006-01-19
US7776924B2 (en) 2010-08-17
AU2003278628B2 (en) 2010-09-23
EP1558568A4 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
CN100546976C (zh) 基于硝基苯胺的烷化剂和它们作为前体药物的用途
US6294531B1 (en) Calcilytic compounds
JP4760712B2 (ja) 新規ニトロフェニルマスタードおよびニトロフェニルアジリジンアルコールおよびそれらの対応するリン酸エステルおよびターゲットが決められた細胞毒性剤としてのそれらの使用
US7166738B2 (en) Non-nucleoside reverse transcriptase inhibitors
WO2021113595A1 (en) Phosphorus derivatives as kras inhibitors
JP2006502214A6 (ja) ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用
CN104024229B (zh) 三唑并嘧啶化合物的合成
US20050049310A1 (en) Aryl and heteroaryl compounds, compositions and methods of use
US9556114B2 (en) Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
JP6200603B2 (ja) 化学療法剤としてのβ置換βアミノ酸および類似体
EP1742908A1 (en) Non-nucleoside reverse transcriptase inhibitors
CN106132406B (zh) 作为化疗剂的β-取代的γ-氨基酸和类似物
HU210683B (en) Process for producing n-benzyl-n1-(phenyl-alkyl)-thiourea derivatives and pharmaceutical compositions containing the same
CN1902159B (zh) 新的硝基苯基氮芥和硝基苯基氮丙啶醇以及它们相应的磷酸酯和作为靶向细胞毒素剂的用途
CN110724075A (zh) 酰胺类化合物、包含其的药物组合物、其制备方法及其用途
MXPA06004635A (en) Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091007

Termination date: 20131008